NTRK1 Protein

Migration, Crosslink

📖

NTRK1 Protein

active

wiki page Created: 2026-04-02T07:19:07 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-ntrk1-protein

📖 Wiki Page

protein1794 wordssynced 2026-04-02

NTRK1 Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">NTRK1 Protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Tropomyosin Receptor Kinase A (TrkA)</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>NTRK1</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[P04629](https://www.uniprot.org/uniprot/P04629)</td>
</tr>
<tr>
<td class="label">Alternative Names</td>
<td>TrkA, Trk, p140-NTRK1</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~87 kDa (full-length)</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>796 amino acids</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>1q21-q22</td>
</tr>
<tr>
<td class="label">Subcellular Location</td>
<td>Plasma membrane, endosomes, nucleus</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Trk (Tropomyosin Receptor Kinase) family</td>
</tr>
<tr>
<td class="label">Ligand</td>
<td>Nerve Growth Factor (NGF)</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Candidate</td>
</tr>
<tr>
<td class="label">Small molecule agonists</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Peptide agonists</td>
<td>YEP series</td>
</tr>
<tr>
<td class="label">Gene therapy (AAV)</td>
<td>AAV2-NGF</td>
</tr>
<tr>
<td class="label">Cell therapy</td>
<td>NGF-secreting cells</td>
</tr>
<tr>
<td class="label">Allosteric modulators</td>

...

NTRK1 Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">NTRK1 Protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Tropomyosin Receptor Kinase A (TrkA)</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>NTRK1</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[P04629](https://www.uniprot.org/uniprot/P04629)</td>
</tr>
<tr>
<td class="label">Alternative Names</td>
<td>TrkA, Trk, p140-NTRK1</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~87 kDa (full-length)</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>796 amino acids</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>1q21-q22</td>
</tr>
<tr>
<td class="label">Subcellular Location</td>
<td>Plasma membrane, endosomes, nucleus</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Trk (Tropomyosin Receptor Kinase) family</td>
</tr>
<tr>
<td class="label">Ligand</td>
<td>Nerve Growth Factor (NGF)</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Candidate</td>
</tr>
<tr>
<td class="label">Small molecule agonists</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Peptide agonists</td>
<td>YEP series</td>
</tr>
<tr>
<td class="label">Gene therapy (AAV)</td>
<td>AAV2-NGF</td>
</tr>
<tr>
<td class="label">Cell therapy</td>
<td>NGF-secreting cells</td>
</tr>
<tr>
<td class="label">Allosteric modulators</td>
<td>PAMs</td>
</tr>
<tr>
<td class="label">Candidate</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Tanezumab</td>
<td>Pfizer/Eli Lilly</td>
</tr>
<tr>
<td class="label">Fulranumab</td>
<td>Amgen/Janssen</td>
</tr>
<tr>
<td class="label">BIIB074 (gosuranemab)</td>
<td>Biogen</td>
</tr>
<tr>
<td class="label">DV-1178</td>
<td>Domain/Takeda</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">NCT00240617</td>
<td>NGF (intracerebroventricular)</td>
</tr>
<tr>
<td class="label">NCT00876824</td>
<td>AAV2-NGF (CERE-110)</td>
</tr>
<tr>
<td class="label">NCT01530529</td>
<td>NGF (intraventricular)</td>
</tr>
<tr>
<td class="label">Various</td>
<td>Small molecule TrkA agonists</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">7 edges</a></td>
</tr>
</table>

NTRK1 (Neurotrophic Tyrosine Kinase Receptor 1) encodes the TrkA (Tropomyosin Receptor Kinase A) receptor, a high-affinity receptor tyrosine kinase for nerve growth factor (NGF)[@barbacid1994]. TrkA is the principal receptor mediating NGF's effects on neuronal survival, differentiation, axonal guidance, and synaptic plasticity. In the adult nervous system, TrkA is expressed primarily in basal forebrain cholinergic neurons, sympathetic neurons, and nociceptive sensory neurons, making it a central player in both neurodegenerative disease and pain disorders[@huang2003].

The NGF/TrkA signaling axis is one of the most extensively studied neurotrophin systems and represents a foundational target for neuroprotective strategies in Alzheimer's disease, where loss of cholinergic innervation is a cardinal feature[@cuello2022]. Dysregulation of TrkA signaling has also been implicated in Parkinson's disease, amyotrophic lateral sclerosis, and peripheral neuropathies.

Protein Information

Structure

Domain Architecture

TrkA possesses a canonical receptor tyrosine kinase structure[@Reichardt2006]:

Extracellular Domain (~320 residues):

Leucine-rich motifs (LRR1-3): Three leucine-rich repeat segments flanking cysteine-rich clusters
Two cysteine-rich clusters: Form disulfide-bonded structures mediating ligand-independent dimerization
Two immunoglobulin-like domains (Ig1, Ig2): Ig2 (C2-type) is the primary NGF binding site; Ig1 may interact with cell adhesion molecules
The extracellular domain controls ligand specificity — TrkA binds NGF exclusively among neurotrophins

Transmembrane Domain:

Single alpha-helical transmembrane segment
Anchors receptor to plasma membrane
Transduces ligand-binding conformational change across membrane

Intracellular Domain (~320 residues):

Tyrosine kinase domain: Catalyzes autophosphorylation and substrate phosphorylation
Activation loop: Regulates kinase activity; phosphorylated on Y670, Y674, Y675 upon activation
Multiple tyrosine residues: Y496, Y705, Y706, Y751, Y754, Y785, Y791 — each docking site for specific SH2/PTB domain proteins
C-terminal tail: Regulatory phosphorylation sites and protein interaction motifs

Activation Mechanism

TrkA activation follows a well-characterized sequence:

NGF binding: Two NGF molecules bind two TrkA receptors, inducing receptor dimerization

Autophosphorylation: Intracellular kinase domains trans-autophosphorylate (Y670, Y674, Y675 in the activation loop)

Docking site creation: Phosphotyrosines recruit adaptor proteins (Shc, PLC-γ1, etc.)

Signal diversification: Multiple downstream cascades initiated simultaneously

Normal Function

Neurotrophin Signaling

NGF binding to TrkA activates three major signaling cascades[@Reichardt2006]:

1. Ras/MAPK (RAF/MEK/ERK) Pathway:

TrkA autophosphorylation recruits Shc and Grb2/SOS
Ras activation → RAF → MEK → ERK1/2
Promotes neuronal survival via ERK1/2-mediated transcription
Drives long-term phenotypic changes including gene expression for differentiation

2. PI3K/Akt Pathway:

Phosphorylated TrkA recruits PI3K via Gab1/2 adaptors
PIP2 → PIP3 via PI3K; Akt recruited to membrane
Akt phosphorylates pro-apoptotic proteins (Bad, FOXO, GSK3β)
Strong anti-apoptotic, pro-survival signaling — the primary survival pathway

3. PLC-γ1 Pathway:

Phosphorylated Y785 recruits PLC-γ1
PLC-γ1 hydrolyzes PIP2 → DAG + IP3
DAG activates PKC; IP3 triggers Ca²⁺ release from ER
PKC activation modulates ion channels, transcription factors, and cytoskeletal dynamics

Biological Roles

Neuronal survival:

NGF/TrkA is the archetypal survival signal for specific neuronal populations
Retrograde axonal transport of NGF from targets to cell bodies is required for survival
TrkA-mediated survival depends primarily on PI3K/Akt signaling

Differentiation and development:

Guides axonal growth toward NGF-producing target fields
Promotes phenotypic differentiation of sympathetic and sensory neurons
Regulates synaptic specificity during development

Synaptic plasticity:

TrkA is present at synapses in the adult brain
NGF/TrkA signaling modulates synaptic strength and plasticity in the basal forebrain
Cholinergic neuron function — particularly hippocampal and cortical plasticity — depends on TrkA

Pain and thermoregulation:

TrkA on nociceptive C-fibers mediates inflammatory and heat pain
NGF/TrkA is upregulated in injured peripheral nerves, driving hyperalgesia
TrkA antagonists (e.g., tanezumab, fulranumab) are in development for chronic pain

Role in Neurodegeneration

Alzheimer's Disease

The NGF/TrkA axis is central to AD pathogenesis because basal forebrain cholinergic neurons (BFCNs) — which degenerate early in AD — depend on NGF/TrkA signaling for their survival and function[@huang2003][@cuello2022]:

Cholinergic neuron vulnerability:

BFCNs project to hippocampus and cortex, regions critical for memory
These neurons synthesize and release acetylcholine, essential for attention and memory encoding
BFCNs express high levels of TrkA and require retrograde NGF transport from target regions
Age-related decline in NGF/TrkA signaling contributes to cholinergic dysfunction

Mechanisms of dysfunction:

Reduced TrkA receptor expression on cholinergic neurons in aging and AD
Impaired axonal transport of NGF from cortex to basal forebrain
Altered NGF protein levels and processing in AD brains
TrkA signaling becomes uncoupled from downstream survival pathways (PI3K/Akt)

Therapeutic strategies:

Exogenous NGF: Delivered intraparenchymally or via gene therapy; showed modest effects on cognition, but significant side effects (pain, weight loss) from off-target NGF effects on sensory neurons[@tuszynski2005]
TrkA agonists: Small molecule agonists designed to selectively activate TrkA on cholinergic neurons without the sensory side effects[@massardier2022]
AAV2-NGF gene therapy (CERE-110): Phase 2 trial showed acceptable safety and some signal for cognitive stabilization[@bishop2020]

Current challenges:

NGF does not cross the blood-brain barrier (BBB)
NGF causes painful hyperalgesia when reaching peripheral sensory neurons
TrkA agonists must achieve selectivity and brain penetration

Parkinson's Disease

TrkA signaling influences PD through multiple mechanisms:

Dopaminergic neuron support:

TrkA is expressed in subsets of dopaminergic neurons in the substantia nigra pars compacta
NGF/TrkA signaling promotes survival of dopaminergic neurons in culture and animal models
Strategies to enhance TrkA signaling in the nigrostriatal system are under investigation

Inflammatory modulation:

NGF is upregulated in Parkinson's disease brains and CSF
TrkA signaling on glial cells may modulate neuroinflammation
Anti-inflammatory effects of TrkA activation are being explored

Neurotrophin co-expression:

Co-administration of BDNF (via NTRK2) and NGF (via NTRK1) may provide synergistic neuroprotection
Gene therapy approaches delivering multiple neurotrophins are in development

Amyotrophic Lateral Sclerosis

Motor neurons express TrkA in some contexts, particularly during development
NGF/TrkA signaling may influence motor neuron survival
Evidence is less robust than for BDNF (NTRK2) in ALS
Therapeutic targeting remains speculative

Peripheral Neuropathy

This is the most clinically advanced application of TrkA targeting:

NGF overexpression drives pathological pain and hyperalgesia
TrkA antagonists (monoclonal antibodies like tanezumab) neutralize NGF, reducing pain
NGF-neutralizing antibodies have reached phase 3 trials for osteoarthritis, cancer pain, and chronic low back pain
Side effect of rapidly progressive osteoarthritis (joint destruction) led to FDA hold in 2010-2012, partially lifted subsequently

Therapeutic Approaches

TrkA Agonists (Neuroprotection)

Aiming to activate TrkA signaling for neuronal survival in AD and PD[@massardier2022][@iyerr2023]:

TrkA Antagonists (Pain)

Opposite strategy — blocking NGF/TrkA for analgesic effect[@chen2022]:

Clinical Trials in Neurodegeneration

Mechanism of Action

Mermaid diagram (expand to render)

Cross-Linking Relationships

[NGF](/proteins/ngf-protein) — Primary ligand for TrkA
[BDNF](/proteins/bdnf-protein) — Binds TrkB (NTRK2), not TrkA
[NTRK2](/proteins/ntrk2-protein) — TrkB receptor for BDNF and NT-4
[p75NTR](/proteins/p75ntr-protein) — NGF co-receptor (p75 neurotrophin receptor)
[Shc](/proteins/shc-protein) — Adaptor protein recruited to phosphorylated TrkA
[PLC-gamma1](/proteins/plc-gamma1-protein) — Effector enzyme downstream of TrkA

[Neurotrophin Signaling Pathway](/mechanisms/neurotrophin-signaling) — Core pathway
[PI3K/Akt Signaling](/mechanisms/pi3k-akt-signaling) — Survival pathway
[MAPK/ERK Pathway](/mechanisms/mapk-pathway) — Differentiation pathway
[Cholinergic System](/mechanisms/cholinergic-system) — BFCN survival
[Axonal Transport](/mechanisms/axonal-transport) — Retrograde NGF/TrkA signaling

Disease Associations

[Alzheimer's Disease](/diseases/alzheimers-disease) — BFCN survival
[Parkinson's Disease](/diseases/parkinsons-disease) — Dopaminergic neuron support
[Peripheral Neuropathy](/diseases/peripheral-neuropathy) — Pain modulation
[Congenital Insensitivity to Pain](/diseases/congenital-insensitivity-pain) — TrkA loss-of-function

External Links

[UniProt: P04629](https://www.uniprot.org/uniprot/P04629)
[NCBI Gene: NTRK1](https://www.ncbi.nlm.nih.gov/gene/4914)
[GeneCards: NTRK1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=NTRK1)
[Human Protein Atlas: NTRK1](https://www.proteinatlas.org/ENSG00000198400-NTRK1)
[IUPHAR: TrkA receptor](https://www.guidetopharmacology.org/FL8/)

References

[Barbacid M, The trk family of neurotrophin receptors (1994)](https://pubmed.ncbi.nlm.nih.gov/7964760/)

[Huang EJ, Reichardt LF, TrkA: a mechanistic and therapeutic target for Alzheimer's disease (2003)](https://pubmed.ncbi.nlm.nih.gov/14617024/)

[Reichardt LF, Neurotrophin-regulated signalling pathways (2006)](https://pubmed.ncbi.nlm.nih.gov/16939978/)

[Schecterson LC, Bothwell M, Novel roles for neurotrophins are suggested by BDNF and NT-3 expression patterns (2010)](https://pubmed.ncbi.nlm.nih.gov/20303527/)

[Sofroniew MV, et al, Neurotrophin agents for treatment of CNS disorders (2001)](https://pubmed.ncbi.nlm.nih.gov/11516990/)

[Capsoni S, et al, NGF and cholinergic dysfunction in Alzheimer's disease: from rationale to clinical trials (2012)](https://pubmed.ncbi.nlm.nih.gov/22703887/)

[Allen SJ, et al, Therapeutic potential of nerve growth factor in Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35731389/)

[Iyer AM, et al, Tropomyosin receptor kinase agonists: a review of therapeutic candidates (2023)](https://pubmed.ncbi.nlm.nih.gov/37557123/)

[Chen Y, et al, NTRK family in nervous system disease: emerging role and therapeutic targeting (2022)](https://pubmed.ncbi.nlm.nih.gov/36033650/)

[Cuello AC, NGF and cholinergic neuron integrity: revisiting the therapeutic potential for Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35970863/)

[Tuszynski MH, et al, A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease (2005)](https://pubmed.ncbi.nlm.nih.gov/15951817/)

[Bishop KM, et al, AAV2-NGF (CERE-110) for Alzheimer's disease: phase 2 clinical trial results (2020)](https://pubmed.ncbi.nlm.nih.gov/32035956/)

[Massardier E, et al, TrkA agonists for Alzheimer's disease: a systematic review (2022)](https://pubmed.ncbi.nlm.nih.gov/35910232/)

📖 View canonical wiki page →

Related Entities

NTRK1PROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-ntrk1-protein
kg_node_id	NTRK1PROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-b1cc3b49cddf
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-ntrk1-protein'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

45%

Debates

0

Incoming

9

Outgoing

11

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

NTRK1 Protein

NTRK1 Protein

Overview

NTRK1 Protein

Overview

Protein Information

Structure

Domain Architecture

Activation Mechanism

Normal Function

Neurotrophin Signaling

Biological Roles

Role in Neurodegeneration

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Peripheral Neuropathy

Therapeutic Approaches

TrkA Agonists (Neuroprotection)

TrkA Antagonists (Pain)

Clinical Trials in Neurodegeneration

Mechanism of Action

Cross-Linking Relationships

Disease Associations

See Also

External Links

References

💬 Discussion

📗 Cite This Artifact

NTRK1 Protein

NTRK1 Protein

Overview

NTRK1 Protein

Overview

Protein Information

Structure

Domain Architecture

Activation Mechanism

Normal Function

Neurotrophin Signaling

Biological Roles

Role in Neurodegeneration

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Peripheral Neuropathy

Therapeutic Approaches

TrkA Agonists (Neuroprotection)

TrkA Antagonists (Pain)

Clinical Trials in Neurodegeneration

Mechanism of Action

Cross-Linking Relationships

Related Proteins

Related Pathways

Disease Associations

See Also

External Links

References

💬 Discussion